The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations.


Autoria(s): Bladen C.L.; Salgado D.; Monges S.; Foncuberta M.E.; Kekou K.; Kosma K.; Dawkins H.; Lamont L.; Roy A.J.; Chamova T.; Guergueltcheva V.; Chan S.; Korngut L.; Campbell C.; Dai Y.; Wang J.; Bari?ić N.; Brabec P.; Lahdetie J.; Walter M.C.; Schreiber-Katz O.; Karcagi V.; Garami M.; Viswanathan V.; Bayat F.; Buccella F.; Kimura E.; Koeks Z.; van den Bergen J.C.; Rodrigues M.; Roxburgh R.; Lusakowska A.; Kostera-Pruszczyk A.; Zimowski J.; Santos R.; Neagu E.; Artemieva S.; Rasic V.M.; Vojinovic D.; Posada M.; Bloetzer C.; Jeannet P.Y.; Joncourt F.; Díaz-Manera J.; Gallardo E.; Karaduman A.A.; Topaloğlu H.; El Sherif R.; Stringer A.; Shatillo A.V.; Martin A.S.; Peay H.L.; Bellgard M.I.; Kirschner J.; Flanigan K.M.; Straub V.; Bushby K.; Verschuuren J.; Aartsma-Rus A.; Béroud C.; Lochmüller H.
Data(s)

2015

Resumo

Analyzing the type and frequency of patient-specific mutations that give rise to Duchenne muscular dystrophy (DMD) is an invaluable tool for diagnostics, basic scientific research, trial planning, and improved clinical care. Locus-specific databases allow for the collection, organization, storage, and analysis of genetic variants of disease. Here, we describe the development and analysis of the TREAT-NMD DMD Global database (http://umd.be/TREAT_DMD/). We analyzed genetic data for 7,149 DMD mutations held within the database. A total of 5,682 large mutations were observed (80% of total mutations), of which 4,894 (86%) were deletions (1 exon or larger) and 784 (14%) were duplications (1 exon or larger). There were 1,445 small mutations (smaller than 1 exon, 20% of all mutations), of which 358 (25%) were small deletions and 132 (9%) small insertions and 199 (14%) affected the splice sites. Point mutations totalled 756 (52% of small mutations) with 726 (50%) nonsense mutations and 30 (2%) missense mutations. Finally, 22 (0.3%) mid-intronic mutations were observed. In addition, mutations were identified within the database that would potentially benefit from novel genetic therapies for DMD including stop codon read-through therapies (10% of total mutations) and exon skipping therapy (80% of deletions and 55% of total mutations).

Identificador

https://serval.unil.ch/?id=serval:BIB_05A0E8F0DE35

isbn:1098-1004 (Electronic)

pmid:25604253

doi:10.1002/humu.22758

isiid:000352304200002

Idioma(s)

en

Fonte

Human Mutation, vol. 36, no. 4, pp. 395-402

Tipo

info:eu-repo/semantics/article

article